Kyttaro Therapeutics
Kyttaro Therapeutics was incorporated in the US in 2021 to commercialize technologies developed by the founders of Apceth Biopharma GmbH since 2007. The company is headquartered in New York, with research operations in Germany. Kyttaro Therapeutics is a development-stage platform technology company with a unique patent portfolio in clinical applications of mesenchymal stem cells (MSCs) for treatment of diseases with a high, unmet clinical need. Kyttaro’s expertise and intellectual property are based on 15 years of research and development in Germany and around the world in cutting-edge applications for MSC Alpha-1 Antitrypsin (MSC-AAT), MSC Cytokines (MSC-Cyt) and MSC-Klotho.
7-day free trial · no credit card
Verified contacts
2
available on Kipplo
LinkedIn employees
4
1 to 10 range
Open roles
—
no listings
Distinct roles
1
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 2 verified contacts at Kyttaro Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
2 contacts with verified email or phone · masked until revealed.
- KM
Kate M.
Board Member · General Business & Management
EmailPhone - KM
Kate McDonough
Board Member · General Business & Management
EmailPhone
Showing 2 of 2 verified contacts
Top roles at Kyttaro Therapeutics
1 distinct titles indexed · top 1 shown.
- 2board member
Sign up to unlock all 2 contacts at Kyttaro Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 2 verified contacts at Kyttaro Therapeutics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.